AIM ImmunoTech (AIM) – Momentum Movers
-
AIM ImmunoTech (AIM) Announces Positive Data from Phase 2a Study Evaluating Ampligen as a Component of a Chemokine Modulatory Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver
-
AIM ImmunoTech (AIM) Enters Material Transfer and Research Agreement with Japan's National Institute of Infectious Diseases and Shionogi to Test COVID-19 Therepy
-
Back to AIM Stock Lookup